LONDON, September 23 — A large prospective study has found that a multicancer blood test detected cancer signals across 17 broad cancer types, including ovarian, lung and breast cancers, according to findings published in a peer-reviewed journal. The test correctly predicted cancer diagnoses in 60.3% of cases, with a specificity of 99.64%. In plain terms, the sensitivity figure means the test found cancer in about six out of ten people who actually had the disease.
The specificity figure points to a very low false-positive rate — the test rarely flags cancer in healthy individuals. Researchers designed the test to pick up circulating tumour DNA and other biomarkers in blood, offering a potential non-invasive route to early cancer detection.
The 17 cancer types covered were not individually listed in the source material, though the study specifically highlights ovarian, lung and breast cancers among them.
Why the study design matters
The work was prospective, meaning participants were followed over time to see who developed cancer. That approach strengthens the evidence compared with retrospective studies, which look backwards at existing records. The research involved a large number of participants, though the exact sample size was not provided in the source material.
Performance varied by cancer type and stage, but no breakdown was given. The source material also did not specify the test’s name, the company or institution behind its development, the journal of publication, the lead authors or their affiliations.
The follow-up period, the cost and availability of the test, and whether it is intended for average-risk individuals or those at higher risk were likewise not stated. The encouraging part is what such a result could mean down the line. The findings could have significant implications for cancer screening, potentially leading to earlier detection and improved outcomes.
But the test is not yet approved for clinical use, and further research is needed to validate its effectiveness in broader populations.
What to watch next
Several questions remain open in the published record. The study’s results were not compared with existing screening methods such as mammography or low-dose CT scans, and its performance was not reported across different demographic groups. No regulatory submissions or commercial partnerships were mentioned, and the source material included no quotes from researchers or independent experts.
For now, the finding adds to the evidence base on blood-based cancer detection and will need replication and broader validation before it can reach routine care. Patients should talk to their doctor about which screening tests are appropriate for them. Consult your doctor for medical advice.
